Anti-Human AXL Recombinant Antibody (Hz1613F12) (CAT#: TAB-1094CL)

Figure 1 ELISA experiments studying binding on rhAxl-Fc protein of both m1613F12 and hz1613F12.

Figure 2 Binding of hz1613F12 and hz1613F12-24 DAR4 and DAR2 to SN12C human renal tumor cells as determined by FACS analysis. Data represent the mean intensity of fluorescence obtained over a range dose of antibody or ADC.

Figure 3 Binding of hz1613F12 and of hz1613F12-24 DAR4 and hz1613F12-24 DAR2 on rhAxl-Fc immobilized protein as determined by ELISA. Data represent the optical densities obtained over a range dose of the tested antibodies. Data were analysed using Prism application.

Figure 4 Binding of hz1613F12 and hz1613F12-33 DAR4 to SN12C human renal tumor cells as determined by FACS analysis. Data represent the mean intensity of fluorescence obtained over a range dose of antibody or ADC.

Figure 5 Binding of hz1613F12 and of hz1613F12-33 DAR4 on rhAxl-Fc immobilized protein as determined by ELISA. Data represent the optical densities obtained over a range dose of the tested antibodies. Data were analysed using Prism application.

Figure 6 Concentration response cytotoxicity curves for hz1613F12-24 in Axl+SN12C (●) and in the control Axl- MCF7 (□) cell lines. A-at Day 3, B-at Day 6. Values of the EC₅₀ concentration was determined using Prism application with the regression analysis for each curve.